Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salsalate for Progressive Supranuclear Palsy
NCT02422485Phase 1Completed
- Start
- Apr 2015
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Amigesic in progressive supranuclear palsy (PSP). Primary endpoint: Drug Limiting Toxicity at 6 months. Started Apr 2015; status: completed.
02
Drugs
Amigesic
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT02422485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02422485.